8-Hydroxy-1,11-eremophiladien-9-one is a minor oxygenated eremophilane ketone reported from Eremophila mitchellii wood oil, the source of Buddha wood essential oil. The accessible evidence base is narrow but usable: a 2011 phytochemistry paper purified and structurally assigned the compound, documented it as a minor wood-oil constituent, and reported in-vitro cytotoxicity in a murine lymphoblast assay. That means AromaForge should frame this constituent as a Buddha wood identity marker with limited early preclinical data rather than a clinically established active.
Chemical identity and composition
The strongest accessible identity source is the 2011 Phytochemistry paper on Eremophila mitchellii oils and isolated eremophilanes, which purified 8-hydroxy-1,11-eremophiladien-9-one and reported NMR and mass-spectral data. The same paper notes that this compound can co-elute with santalcamphor by GC-MS, making authenticated reference data important when assigning minor peaks in Buddha wood profiles.
Aroma and practical use
- Use the recorded woody, earthy, buddha-wood-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
The 2011 Eremophila mitchellii phytochemistry study purified 8-hydroxy-1,11-eremophiladien-9-one from wood oil, described it as a minor constituent, and reported an IC50 of 76 micrograms per mL against P388D1 mouse lymphoblast cells.
The 2011 Eremophila mitchellii phytochemistry study purified 8-hydroxy-1,11-eremophiladien-9-one from wood oil, described it as a minor constituent, and reported an IC50 of 76 micrograms per mL against P388D1 mouse lymphoblast cells.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A publicly posted Buddha wood GC-MS chromatogram listed 8-hydroxy-1,11-eremophiladien-9-one at 1.61%, reinforcing that it tends to appear as a minor supporting constituent in commercial wood-oil profiles.
A publicly posted Buddha wood GC-MS chromatogram listed 8-hydroxy-1,11-eremophiladien-9-one at 1.61%, reinforcing that it tends to appear as a minor supporting constituent in commercial wood-oil profiles.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific human safety study, dermal restriction, or phototoxicity review for isolated 8-hydroxy-1,11-eremophiladien-9-one was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The accessible bioactivity evidence is limited to an in-vitro cytotoxicity assay and should not be translated into therapeutic or anticancer claims.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (7)
- No public CAS number or broad registry record was verified for this specific isomer in the reviewed accessible sources.
- The accessible direct bioactivity record is limited to one in-vitro cytotoxicity assay.
- No constituent-specific human safety or topical-use data were located.
- A 2026-07-13 targeted web search for IFRA/RIFM/Tisserand dermal-limit, sensitization, or phototoxicity data specific to 8-hydroxy-1,11-eremophiladien-9-one returned no authoritative results; this obscure eremophilane ketone appears to have no publicly available dermal safety data. The previously listed dermal_limit_pct of 2 was an unsourced placeholder and has been cleared to null.
- Second-pass 2026-07-13 retry tried a different angle: a direct search for a CAS number specific to '8-hydroxy-1,11-eremophiladien-9-one' turned up only related but distinct eremophilane compounds (eremophilone CAS 562-23-2; petasol/3-hydroxy-9,11-eremophiladien-8-one CAS 64236-38-0; 9,11-eremophiladien-8-one PubChem CID 14482758) and no CAS entry matching this specific isomer. No CAS, IFRA, RIFM, or Tisserand data were located; cas remains null and dermal fields remain null/false.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.